{"id": "chatcmpl-8JX8j2b5mTETXMX4Leze3HlKi4yiy", "object": "chat.completion", "created": 1699666313, "model": "gpt-4-0613", "choices": [{"index": 0, "message": {"role": "assistant", "content": "1. A study was conducted on the effects of add-on prolonged-release melatonin (PRM) to standard therapy on cognitive functioning and sleep.\n2. The study involved 80 patients.\n3. The patients were diagnosed with mild to moderate Alzheimer's Disease (AD).\n4. The patients were receiving standard therapy, which included acetylcholinesterase inhibitors with or without memantine.\n5. The patients in the study were both men and women.\n6. The percentage of men in the study was 50.7%.\n7. The percentage of women in the study was 49.3%.\n8. The average age of the patients in the study was 75.3 years.\n9. The age range of the patients in the study was between 52 and 85 years.\n10. The dosage of prolonged-release melatonin (PRM) used in the study was 2 mg.\n11. Some patients in the study had insomnia as a comorbidity."}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 123, "completion_tokens": 198, "total_tokens": 321}, "temperature": 0, "max_tokens": 512, "top_p": 1, "frequency_penalty": 0, "presence_penalty": 0, "messages": [{"role": "system", "content": "Statement: The effects of add-on prolonged-release melatonin (PRM) (2 mg) to standard therapy on cognitive functioning and sleep were investigated in 80 patients (men [50.7%], women [49.3%], average age 75.3 years [range, 52\u201385 years]) diagnosed with mild to moderate AD, with and without insomnia comorbidity, and receiving standard therapy (acetylcholinesterase inhibitors with or without memantine).\n\nList all the facts we explicitly know from the statement. Make each fact as atomic as possible."}]}